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Respiratory syncytial virus (RSV) is a major pathogen that infects lower respiratory tract
and causes a common respiratory disease. Despite serious pathological consequences
with this virus, effective treatments for controlling RSV infection remain unsolved, along
with poor innate immune responses induced at the initial stage of RSV infection. Such
a poor innate defense mechanism against RSV leads us to study the role of alveolar
macrophage (AM) that is one of the primary innate immune cell types in the respiratory
tract and may contribute to protective responses against RSV infection. As an effective
strategy for enhancing anti-viral function of AM, this study suggests the intranasal
administration of Bacillus subtilis spore which induces expansion of AM in the lung
with activation and enhanced production of inflammatory cytokines along with several
genes associated with M1 macrophage differentiation. Such effect by spore on AM
was largely dependent on TLR-MyD88 signaling and, most importantly, resulted in a
profound reduction of viral titers and pathological lung injury upon RSV infection. Taken
together, our results suggest a protective role of AM in RSV infection and its functional
modulation by B. subtilis spore, which may be a useful and potential therapeutic
approach against RSV.
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INTRODUCTION
Respiratory syncytial virus (RSV) causes serious disease symptoms of bronchiolitis and acute
lower respiratory tract infection resulting in up to 200,000 annual deaths worldwide, especially
for the infants and elderly (Nair et al., 2010). Recent study has also suggested that children
younger than 6 months old suffering from RSV amounted to 1.4 million hospital admissions and
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27,300 for in-hospital death (Shi et al., 2017). Despite the
numerous trials, effective preventive strategies against RSV
infection have been limited and turned out to be unsuccessful.
This is because of the unique ability of RSV to disarm host
of both innate and adaptive immunity (Meng et al., 2014)
causing overall failure of host immune defense mechanisms,
which is mainly due to non-structural 1 and 2 proteins.
Indeed, a poor innate response has previously been well
documented particularly at the initial stage of RSV infection
(Marr et al., 2013) and several attempts have been made to
improve this stage in RSV infection. In this regard, it has
been suggested that successful protection against RSV can
be mediated by activation of innate immune cells via toll-
like receptor (TLR) 2 and 4 stimulation (Kurt-Jones et al.,
2000; Murawski et al., 2009), but not by caspase-1 pathway
(Shim and Lee, 2015).
One of the primary innate immune cell types in the lung is
alveolar macrophages (AM), which play a pivotal role to maintain
homeostasis and to induce effective defense mechanism. AMs
have unique properties compared to other macrophages in
different tissues because they have direct contact with external
environment, which could allow rapid and direct recognition
of antigens derived from invading pathogens or allergens
followed by the initiation of immune responses (Hashimoto
et al., 2011; Herold et al., 2011). Recent studies have shown
that failure of early AM-mediated defense response caused
insufficient protection against various viral pathogens infecting
respiratory tracts and led to diminished recruitment of immune
cells followed by disrupted lung homeostasis (Maus et al.,
2002; Snelgrove et al., 2008). Despite the importance of AMs
in various respiratory viral diseases, the precise role and
protective mechanisms of AM in RSV infection are yet to
be investigated.
Previous attempts using probiotics have gained an insight for
the priming innate immune system where the administration of
such probiotics induced a rapid activation of innate immunity
and consequently enhanced protective efficacy against respiratory
viral infection (Garcia-Crespo et al., 2013; Park et al., 2013;
Lee et al., 2016). Furthermore, spore derived from probiotics,
as we used in this study, is known to be one of the
alternatives not only for inducing enhanced innate immune
responses but also for safety and stability (Hong et al., 2008).
Bacillus subtilis has been known to change its status into
spore form under the harsh circumstances such as starvation.
After sporulation, it can survive with resistance to heat, cold,
or other enzymatic assaults (Tan and Ramamurthi, 2014).
Because of their stability, several researchers have tried to
use spores as probiotics or adjuvants to enhance the health
and to protect against infections caused by microbes such
as influenza virus (Song et al., 2012) or Clostridium difficile
(Colenutt and Cutting, 2014) in mice and human trials
(Lefevre et al., 2015, 2017).
In this study, we tried to use B. subtilis-derived spore to
overcome RSV infection and investigated whether and how
B. subtilis-derived spore would influence on the AMs to induce
effective innate immunity and subsequently to protect host
from RSV infection.
RESULTS
Intranasal Delivery of B. subtilis Spore
Enhanced Anti-viral Immunity to RSV
Infection
It has been reported that in vivo administration of prebiotics
or probiotics such as Lactobacillus can facilitate protective
immunity against influenza virus infection (Kiso et al., 2013;
Lee et al., 2013). These previous reports prompted us to test
the potential of bacterial particular substance, B. subtilis-derived
spore to protect against RSV infection. To address this, a group
of mice was administered with or without spore intranasally (i.n.)
prior to RSV infection and then infected them with RSV. The
effect of spore was clear in body weight loss; untreated control
mice lost 10–20% total body weight with a peak reduction of
day 2 post-infection (p.i.), which is well-known symptom of
RSV infection in mouse model, whereas mice treated with spore
did not lose their body weight (Figure 1A). It should be noted,
however, that the weight loss after RSV infection appeared to be
transient, which is a limitation of RSV mouse infection model,
so the control mice began to gradually gain weight back to near
normal level by day 4 post-infection. To support the body weight
data, there was about 4–5-fold decrease in viral loads in the lung
of the spore-treated mice compared to those of control mice
(Figure 1B). These results suggest that delivery of B. subtilis spore
not only prevent the pathology, but also help clearance of virus
against RSV infection.
I.n. Administration of B. subtilis Spore
Increases the Number of Alveolar
Macrophages
To identify the cellular mechanism by which B. subtilis spore
influences on anti-viral immunity, we analyzed various innate
immune cells in the lung with or without spore treatment. We
found that there was the most notable increase in AM both in the
lung and bronchoalveolar lavage (BAL) along with inflammatory
monocytes or neutrophils (Figures 1C,D), implicating AMs
might play an important role in mediating innate immunity to
RSV. In line with increased numbers of AM, spore-treated mice
showed increased gene expression of GM-CSF and well-known
M1 macrophage-related cytokines (Murray et al., 2014) including
TNF-α, IFN-γ, IL-12p40, and IL-6 (Supplementary Figure S1).
The cytokine producing ability of spore was also apparent in
protein level of effector cytokines such as IFN-β and IL-12p40
(Figure 1E), which are also categorized in M1 macrophage-
related cytokines. These results suggest that administration of
B. subtilis spore induced significantly enhanced number of AMs,
and augmented expression of effector cytokines which are related
to M1 macrophage differentiation.
Depletion of Alveolar Macrophages
Aggravates Disease Severity in Mice
Infected With RSV
In viral infection condition, it is known that AM have a critical
role during the early phase of infection (Schneider et al., 2014a)
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FIGURE 1 | Pre-treatment with spore through intranasal route reduces the disease severity following RSV infection and induces the population change of alveolar
macrophages (AM) and enhances antiviral effector molecules. Mice were administered with 1 × 109 CFU of spore via i.n. route at 5 days prior to RSV infection with
2 × 106 PFU per mouse (n = 3). (A) Body weight was monitored daily after the infection and (B) viral load in the lungs was analyzed by plaque assay at 4 days
post-infection (DPI). Change of various innate immune cells in the (C) post-lavaged lung and (D) BAL fluid was analyzed by flow cytometry at 0 to 4 DPI. Empty and
filled circles indicate PBS and spore pre-treated mice, respectively. (E) IFN-β and IL-12p40 in BAL fluid were measured by ELISA. Data are expressed as
mean ± S.E.M. for the group. Significant differences from results with the PBS control are ∗P < 0.05; ∗∗P < 0.01; and ∗∗∗P < 0.001, respectively.
because of the alarming failure and lack of scavenger activity
against infected cells (Kumagai et al., 2007; Pribul et al., 2008).
Moreover, AM-depleted mice are unable to deliver the antigen
to dendritic cells for the antigen presentation (Ugonna et al.,
2014) in order to strengthen the following adaptive immune
response. To examine the particular role of AM in RSV infection,
we conducted the depletion of AM by injection of clodronate-
encapsulated liposome (Clod) through the intratracheal (i.t.)
route. As a result, absolute number of AM in the lungs and
BAL from Clod-treated mice declined by approximately 85%
compared to that in control (Supplementary Figure S2) without
significant histological changes (Figure 2C). At day 1 post-
infection of RSV, AM-depleted mice showed a sharp decline in
body weight (Figure 2A) and at day 4, they have significantly
higher viral loads in lung than control (Figure 2B). Pathological
results also showed the severity of infection with displayed
thickened alveolar epithelium, destruction of epithelial walls,
overall alveolar swelling, and the accumulation of immune cells
in the lung (Figure 2C). Furthermore, the accumulation of
inflammatory cells in the interstitial space, bronchi, and vessel
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FIGURE 2 | Mice selectively depleted with AMs fail to protect RSV infection. Mice were injected i.t. with clodronate-encapsulated liposome twice on days 1 and 3
prior to RSV infection. (A) Body weight was monitored daily after the infection and (B) viral load in the lungs was analyzed by plaque assay at 4 DPI (n = 3). At 4 DPI,
perfused lungs were stained with H&E (C) for histological examination by microscopy at 200 × magnifications and (D–G) scored for histopathology. “Cont” indicates
the mice injected with control liposome and “Clod” indicates the mice injected with clodronate-encapsulated liposome. Arrows indicated as follows; orange,
epithelium thickness and destruction; green, pulmonary edema; red, inflammatory cells; and black, cell death. Data are expressed as mean ± S.E.M. for the group.
Significant differences from results with the PBS control are ∗P < 0.05 and ∗∗P < 0.01, respectively.
was apparent in lungs from AM-depleted mice (Figures 2D–G).
Taken together, depletion of AM at the initial phase of RSV
infection leads to exacerbated disease severity coincident with
increased pulmonary inflammation.
Spore Directly Enhances the Antiviral
Function of Alveolar Macrophages
To explore direct role of AM in cellular level and the effect
of B. subtilis spore, AM cell line, MH-S, was treated with
spore for 24 h and then infected with RSV. The number of
plaques of RSV was significantly reduced when the cells were
incubated with spore in a dose-dependent manner (Figure 3A).
Inflammatory cytokines, IL-12p40 and IL-6, in the supernatant
from the cells treated with spore followed by RSV infection
were measured as an initial assessment for their antiviral activity
(Ugonna et al., 2014). The results showed that the spore
treatment led to substantial increase of IL-6 and, to a lesser
extent, IL-12p40 (Figure 3B). These results demonstrated that
B. subtilis spore directly promotes the anti-viral activity of AM,
especially at the early time point after the infection, in a dose-
dependent manner.
Frontiers in Microbiology | www.frontiersin.org 4 March 2019 | Volume 10 | Article 447
fmicb-10-00447 March 8, 2019 Time: 17:38 # 5
Hong et al. B. subtilis Spore Protects Against RSV
FIGURE 3 | Alveolar macrophages pre-treated with spore extend their antiviral effects. MH-S cells were stimulated with spore for 24 h, with a ratio of MH-S:Spore
at = 1:0, 1:1, 1:10, and 1:50. Then, the cells were washed and infected with 1 MOI RSV for 12 h. (A) The viral load was analyzed by using plaque assay and (B) the
production of IL-12p40 and IL-6 was measured by ELISA. Data are expressed as mean ± S.E.M. of three replicates. ∗ and ∗∗ indicate significant differences at
P < 0.05 and P < 0.01, respectively.
Alveolar Macrophages Activated by
Spore Have a Pivotal Protective Role in
Mice Infected With RSV
To validate direct involvement of spore-activated AM for the
protection from RSV infection in vivo, we depleted the AMs in
spore pre-administered mice before RSV infection. As mentioned
above, mice treated with spore did not have any significant
weight loss (Figure 4A), in line with the ability of spore to
clear the virus (Figure 4B). However, when we depleted AM
by clodronate in spore-treated mice, they showed a moderate
decrease of body weight (Figure 4A) and led to viral counts
be increased in the lung (Figure 4B), suggesting that AM play
an important role in the protection against RSV infection by
B. subtilis spore treatment. The spore treatment can efficiently
protect the epithelium and prevent infiltration of immune cells
in alveolus (Figure 4C) and bronchi (Supplementary Figure S3),
which is seen in the pathological score (Figures 4D–G) in
support of the effect of AM. These data suggested that spore
treatment prevents RSV infection efficiently, the effect is partially
dependent on the AM. Taken together, these results support
that the B. subtilis spore enhances host protection against RSV
infection with support of AM.
The Effects of Spore on Protection
Against RSV Infection Are Dependent on
MyD88 Signaling
The next question was which signaling pathways are involved in
the capacity of spore to modulate anti-viral functions of AM.
Since previous reports suggest TLR2 or 4 is in charge of viral
infection as mentioned above, we presumed that spore might
trigger MyD88 signaling upon direct engagement with TLRs on
AM. In support of this idea, we used MyD88−/− mice for RSV
infection model with B. subtilis spore administration. MyD88−/−
mice were unable to induce protective response to RSV infection
with reduced body weight (Figure 5A) and significantly high
viral load (Figure 5B). More importantly, the administration
of spore did not work on the recovery of MyD88−/− mice
at all. Consistent with these data, infiltration of AM in the
lung (Figure 5C) and BAL (Figure 5D) was far less than
wild-type mice and the inflammation with severe destruction
of epithelium was also shown in alveolus (Figures 5E–I) and
bronchi (Supplementary Figure S3) of MyD88−/− mice even
with B. subtilis spore treatment.
To confirm the direct engagement of MyD88 signaling upon
B. subtilis treatment in cellular level, we used bone marrow-
derived macrophages (BMMs) from wild type or MyD88−/−
mouse and treated spore in vitro with RSV infection and
conduct plaque assay with culture supernatant. In the same
context with in vivo data, significantly higher viral loads
were observed in MyD88-deficient BMMs compared to wild-
type BMMs (Figure 6A). As expected, the capability of spore
to reduce viral load was prominent in wild-type BMMs in
a dose-dependent manner; unexpectedly, however, the effect
of spore was, albeit less, also apparent even in MyD88-
deficient BMMs. Consistent with data from viral loads, IL-12p40
production was markedly augmented by spore treatment and
substantially higher in wild-type BMMs than MyD88-deficient
BMMs (Figure 6B).
Taken together, these results suggest that B. subtilis spore can
enhance the protective capacity against RSV infection affecting
directly on the AMs, and these activation and M1-related effector
cytokine production is dependent on MyD88 signal.
DISCUSSION
Importance of AM for host defense mechanism during early viral
infection in respiratory tract is well established, however, the
precise role of AM, especially in mice infected with RSV is less
clear. In the present study, we focused on the specific role of
AM treated with B. subtilis spore in RSV infected mice for their
protection and brought the following four notable findings: (1)
AM have a pivotal role for protection during the initial stage of
RSV infection; (2) Administration of B. subtilis spore induces
the activation of AM with up-regulation of GM-CSF and M1
macrophage-related cytokines; (3) The i.n. delivery of B. subtilis
spore induces the increase of antiviral effector molecules against
RSV infection; and (4) MyD88 signals in the AM are critical for
the protection against RSV.
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FIGURE 4 | Alveolar macrophages in mice intranasally administered with spore play a key role in RSV infection. Mice were intranasally administered with spore at
5 days prior to RSV infection and injected with control or clodronate-encapsulated liposome through intratracheal on days 3 and 1 before the infection and sacrifice
on 4 DPI. (A) Body weight was monitored daily after the infection and (B) viral load in the lung was examined at 4 DPI, respectively (n = 3). (C) At 4 DPI, perfused
lungs were stained with H&E for histological examination by microscopy at 200 × magnifications and (D–G) scored for histopathology. Arrows indicated are as
follows; orange, epithelium thickness and destruction; green, pulmonary edema; red, inflammatory cells; and black, cell death. Significant differences from results
with the PBS control are ∗P < 0.05; ∗∗P < 0.01; and ∗∗∗P < 0.001, respectively.
Induction of innate immune response in the early phase of
viral infection is necessary for host immunity (McGill et al.,
2009; Copenhaver et al., 2014), and thus over the years various
attempts have been tried to improve the innate immunity in
order to achieve the better protection against viral infection.
Delivery of probiotics and their related materials is one of the
strategies (Kiso et al., 2013; Yaqoob, 2014) and in the present
study we sought a potential ability of spore to enhance innate
immunity against RSV in line with other studies (Hong et al.,
2008; McKenney et al., 2013).
It been reported that AM play an important function in diverse
respiratory infections such as a primary recognition of antigens
and scavenger to infected cells (Tate et al., 2010) and that the
absence of AM-mediated defense mechanism led to the failure
of protective immune responses, the exacerbation of pathology,
and the accumulation of debris following pulmonary infection
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FIGURE 5 | Protective mechanism of spore pre-treated mice infected with RSV is dependent on MyD88 signaling in AMs. Wild type or MyD88 knockout mice were
administered i.n. with spore at 5 days prior to RSV infection. (A) Body weight was monitored daily after the infection (n = 3). At 4 DPI, (B) viral load in the lungs was
analyzed by plaque assay and absolute number of AMs in (C) post lavaged lungs, and (D) BAL cells were acquired by flow cytometry. Values with different letters (a,
b, c, d) are significantly different one from another (P < 0.05). (E) Blood-perfused lungs were stained with H&E for histological examination by microscopy at 200×
magnification and (F–I) scored for histopathology at 4 DPI. Arrows indicated are as follow; orange, epithelium thickness and destruction; green, pulmonary edema;
red, inflammatory cells; and black, cell death. Significant differences from results with the PBS control are ∗P < 0.05; ∗∗P < 0.01; and ∗∗∗P < 0.001, respectively.
(Kolli et al., 2014) but the precise role and protective mechanism
of AM in RSV infected mice are yet to be illuminated. Direct
evidence showing important role of AM in the present study
came from in vivo experiment with depletion of AM. The results
showed that the AM-depleted mice suffered from high viral load
and intense pathological episode as shown by the accumulation of
dead cells and debris in bronchi and blood vessels, indicative of
early pulmonary inflammation. All these findings clearly support
the critical role of AM in controlling disease severity of mice
infected with RSV. AM treated with B. subtilis spore rendered
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FIGURE 6 | Bone marrow-derived macrophages pre-treated with spore develop antiviral effects through MyD88-dependent pathway. Wild type or MyD88 knockout
BMMs were treated with spore for 24 h at ratio of spore per number of cells for 0, 1, 10, and 50. Then, the cells were washed and infected with 1 MOI virus for
additional 12 h. (A) Viral titers from wild type or MyD88 knockout BMMs were measured by plaque assay and (B) the production of IL-12p40 was measured by
ELISA. Data are expressed as mean ± S.E.M. for 3 independent experiments. ∗, ∗∗, and ∗∗∗ indicate significant differences at P < 0.05, P < 0.01, and P < 0.001,
respectively.
less susceptible to RSV infection and more importantly, anti-viral
function of spore was markedly reduced upon depletion of AM,
implying AM as a major target for B. subtilis spore as well as a key
player for the protection.
How does then the spore influence on anti-viral function,
differentiation, and/or migration of AM that would potentially
benefit protective immunity to RSV? Our results showed that
mice pre-treated spore through i.n. route rapidly up-regulated
GM-CSF and M1 macrophage-related cytokines such as TNF-α,
IFN-γ, IL-6, and IL-12p40. GM-CSF is a well-known essential
factor for the differentiation (Guilliams et al., 2013), survival
(Shibata et al., 2001), replenishment (Steinwede et al., 2011), and
the ability of host defense (Ghoneim et al., 2013) of macrophages.
Also, IFN-γ could lead monocytes differentiate into classically
activated macrophages (M1-macrophages). This polarization is
important in limiting tissue damage (Barros et al., 2013) and
induces the increase of cytokines that enhance the ability of
AM for the killing of intracellular pathogens (Martinez and
Gordon, 2014). Thus, as a working mechanism for B. subtilis
spore, it is conceivable that pre-treatment with B. subtilis spore
might enhance the viability of macrophages, which promotes
their antiviral functions. Alternatively, B. subtilis spore may
facilitate AM proliferation and/or differentiation, skewing M1
vs. M2 balance toward favoring of M1 macrophage, which
leads to an environment in which immune-stimulatory cytokines
dominate for host protection against RSV. Supporting this
idea, pre-treatment with spore indeed failed to induce TGF-
β and PPAR-γ, which are known to induce differentiation
of immune-suppressive M2 macrophages (Ginhoux, 2014;
Schneider et al., 2014b). However, it is not always better to
have M1 responses than M2 responses depending on how strong
the immune response is and when the response was induced.
It is important to induce appropriate and balanced immune
responses because it has been reported that overwhelming
pro-inflammatory responses with iNOS exacerbate the lung
damage (Mgbemena et al., 2013). In addition, Th2 cytokines
such as IL-4 and IL-13 induced after RSV infection could
alleviate the damage of tissue (Shirey et al., 2010). Whether the
preferences of M1/M2-type cytokines by spore indeed reflect
AM proliferation/differentiation or selective enhancement of
migration will need further investigation.
Besides the preference of M1 cytokines, mere increase of
AM numbers we found after spore treatment would also have
an advantage for protection against RSV infection, given that
AM is known to play a role as reservoirs for inhaled antigens
(Copenhaver et al., 2014) and thus the rapid increase of AM
may effectively boost not only innate immunity but also prime
adaptive immunity. Consistent with these, mice pre-treated
with B. subtilis spore before RSV infection displayed a certain
protective immunity as shown by significantly low level of viral
titer and maintenance of body weight. Furthermore, B. subtilis
spore treatment induced inflammatory monocytes with Ly6C
high phenotype, known to regulate type I IFN signaling during
acute viral pneumonia in mice (Seo et al., 2011) with an ability to
differentiate into macrophages (Geissmann et al., 2010). Indeed,
mice pre-treated with B. subtilis spore showed remarkably high
IFN-β. Recent study showed that AM are the major source
of type I IFNs during RSV infection and an underappreciated
facet of type I IFNs-dependent resistance leads to a cell-extrinsic
responses through rapid recruitment of antiviral inflammatory
monocytes to the site of infection (Goritzka et al., 2015).
It would be important to postulate what are the mechanisms
behind the modulatory ability of spore for AM. The most
plausible explanation is that spore itself and/or its degraded
components acts as a TLR ligand. TLR2 and TLR4 signaling
pathways, in which MyD88 serves as a downstream molecule, are
essential for the protection in RSV infection (Shirey et al., 2010).
Consistent with those reports, in the present study, MyD88−/−
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mice showed persistence of high viral counts in parallel with
impaired body weight gain after the infection suggesting that
MyD88 is indispensable for the protection against RSV infection.
Furthermore, it was evident that MyD88−/− mice failed to
recruit AM into the lung region, irrespective of B. subtilis spore
administration, suggesting that B. subtilis spore-induced increase
of AM in the lung and BAL was dependent on MyD88.
MyD88−/− mice also displayed severe pathological signs
in the lung compared to wild type mice. These results imply
that MyD88-dependent signaling might be the key mechanism
by which AM treated with B. subtilis spore contribute to the
protection of mice against RSV infection. This requirement
of MyD88 signaling may account for the ability of spore to
promote AM capable of producing GM-CSF and M1-related
cytokines, which enhance their viability and M1 signature
cytokines including IFN-γ and TNF-α, as well as producing IFN-
β and IL-12p40, which may serve as an alarm signal and facilitate
IFN-γ production. Whether all these MyD88-dependent effects
by spore are indeed mediated through direct binding on TLR
and whether there are MyD88-independent TLR signaling such
as NOD2 being involved will need to be addressed. Collectively,
our results provided a key modulatory role of B. subtilis spore
in the anti-viral function of AM and have useful implication for
effective treatment against RSV infection.
Even after depletion of AM, to a lesser extent, spore treatment
can reduce the viral load of RSV. There are other possibilities than
macrophages which may contribute to the protective function of
spore against RSV infection. For instance, components derived
from commensal microbes have been reported to induce anti-
microbial peptides from epithelial cells that act as a first
line defense against viral infection (Gomez and Prince, 2008).
Furthermore, TLR2 signal can up-regulate the tight junction
proteins in epithelial cells (Ragupathy et al., 2014) which can
enhance the tolerance to viral infection.
Several studies have been done with B. subtilis spore to protect
against infections in mice and human (Colenutt and Cutting,
2014; Lefevre et al., 2015, 2017). Even though the spores have
been reported to be safe in human trials, safety should be more
elucidated further, for example, on administration of spores in
the respiratory tracts or as subcutaneous injection. In addition,
the status of spore as a live or heat-killed form should be
studied more in terms of safety. Collectively, we proved a key
function of B. subtilis spore in antiviral activity and protection of
lung environment against RSV-induced damage in mice infected
with RSV via MyD88.
MATERIALS AND METHODS
Mice and Ethics Statement
Female BALB/c mice, 6–8 week-old, were purchased from
Orient Bio Inc., Korea. MyD88−/− mice were purchased from
Jackson laboratory (Bar harbor, ME, United States). Animals were
maintained and procedures were performed with approval of
the IACUCs of Seoul National University (Approval No.: SNU-
130527-5) and International Vaccine Institute (Approval No.:
2012-022) in accordance to Laboratory Animal Act of Korean
Ministry of Food and Drug Safety for enhancing the ethics and
reliability on animal testing through appropriate administration
of laboratory animals and animal testing.
Preparation and Isolation of B. subtilis
Spore
Bacillus subtilis was spread in an agar plate containing 3%
Trypticase soy broth (TSB), 0.5% Yeast extract (YE), and
1.5% Bacto Agar (all from BD Biosciences, San Diego, CA,
United States) and incubated at 37◦C for 9 h. One colony was
picked and inoculated in 25 ml of 3% TSB and 0.5% YE liquid
media. Then, it was incubated for 5 h in the shaking incubator
at 150 rpm at 37◦C until the OD value reached between 0.45
and 0.6. For sporulation, culture was transferred to 500 ml of
the autoclaved media containing 5 ml of 10% KCl, 5 ml of
1.2% MgSO4·7H2O (pH 7.6), 0.5 ml of 1 M Ca(NO2)3, 0.01 M
MnCl2, and 1 mM FeSO4. The culture was incubated at 37◦C
for 48 h with shaking at 150 rpm. The cells were collected by
centrifugation at 5516 × g for 10 min, re-suspended in distilled
water, and incubated at 4◦C for 48 h on the rocker. Then, the
cells were sonicated at 35% amplitude (1 watt) for 90 s with 0.5 s
pulse. Spore loaded on the layers of 35, 25, and 15% OptiPrep
Density gradient (Sigma-Aldrich, Wt. Louis, MO, United States)
was centrifuged at 10,000 × g for 40 min at 25◦C without break
for the purification. The spore was washed 3 times with distilled
water and re-suspended in 1 ml of distilled water.
Preparation and Isolation of Respiratory
Syncytial Virus A2
Respiratory syncytial virus A2 strain was amplified as follows:
HEp-2 cells (ATCC, Manassas, VA, United States) were grown
in MEM containing 10% of FBS and 1% of antibiotics (Jang et al.,
2011). When the cells reached at approximately 80% confluence,
the cells were washed and inoculated with 0.01–0.05 MOI of virus
in MEM containing 1% of antibiotics and 25 mM HEPES (Gibco,
Grand Island, NY, United States). The cells were incubated for
2 h at 37◦C, added MEM containing 6% of FBS only, and
then incubated for additional 72–96 h. The cells were scraped
and combined into the conical tubes on ice and centrifuged at
1,400 rpm for 4 min at 4◦C. The cell pellets were collected into
conical tubes, re-suspended with cold conditioned media with
60% sorbitol, sonicated for 15 min in slurry ice and centrifuged
at 4,000–5,000 rpm for 10 min at 4◦C, and then the sonication
and centrifugation step was repeated under the same condition.
The supernatants were transferred into new tubes, centrifuged
at 23,000 rpm for 1 h at 4◦C, and then discarded. The resulting
whitish virus pellet was re-suspended with 500 µl of cold MEM
and the titer was determined by standard RSV plaque assay.
Isolation and Culture of Bone
Marrow-Derived Macrophages and
Macrophage Cell Line
Bone marrow was flushed from femurs and tibias of the mice
using Dulbecco’s Modified Eagle Medium (DMEM, Gibco)
supplemented with 2% FBS (Gibco). Red blood cells were lysed
with ACK lysing buffer (Gibco) and whitish marrow cells were
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seeded in 90× 15 mm Petri dish with complete media containing
10% FBS, 1% antibiotics with 20% L-929 conditioned media
(Zhang et al., 2008) and cultured at 37◦C in humidified incubator
with 5% CO2 for 7 days. On day 3, another 5 ml of fresh complete
media was added to each dish. On day 7, only adherent cells were
collected using non-enzymatic cell dissociation solution (Gibco).
MH-S cells (ATCC, Manassas, VA, United States), mouse AM cell
line, were grown in RPMI-1640 GlutaMax medium containing
10% FBS, 1.5% antibiotics (all from Gibco) in a humidified
incubator with 5% CO2 at 37◦C.
RNA Isolation and Quantitative Real
Time-PCR
For quantitative analysis for the expression of GM-CSF, TNF-α,
IFN-γ, IL-12p40, IL-6, PPAR-γ, and TGF-β1 at mRNA level,
quantitative real time polymerase chain reaction (qRT-PCR)
was conducted. RNA was extracted from perfused lungs using
TRIZOL (Invitrogen, Carlsbad, CA, United States). Total RNA
was isolated by adding chloroform followed by centrifugation
at 4◦C, 12,000 × g for 15 min and addition of isopropanol
for 10 min at room temperature for RNA precipitation. RNA
pellet obtained by washing with 75% ethanol was air dried for
10–15 min. Then it was re-suspended with DEPC distilled water
(Sigma-Aldrich, Wt. Louis, MO, United States) and quantified
with NanoDrop (Amersham Bioscience, United States) at
A260. One microgram of RNA was reverse transcribed into
cDNA and amplified with murine primers specific for GM-CSF
(forward primer: 5′-CTGCCTTAAAGGGACCAAGAGA-
3′, reverse primer: 5′-TTCCGCTGTCCAAGCTGAGT-3′),
TNF-α (forward primer: 5′-GCCAACGGCATGGATCTC-3′,
reverse primer: 5-GTGGGTGAGGAGCACGTAGTC-3′), IFN-γ
(forward primer: 5′-GCCATCGGCTGACCTAGAGA-3′, reverse
primer: 5′-GCAGTGTGTAGCGTTCATTGTCT-3′), IL-12p40
(forward primer: 5′-GAAAGGTGCGTTCCTCGTAGA-3′,
reverse primer: 5′-GGAACACATGCCCACTTGCT-3′), IL-6
(forward primer: 5′-CACAGAGGATACCACTCCCAACA-3′,
reverse primer: 5′-TCAGAATTGCCATTGCACAAC-3′), PPAR-
γ (forward primer: 5′-CAGGAGCCTGTGAGACCAACA-3′,
reverse primer: 5′-ATCAGTGGTTCACCGCTTCTTT-3′), TGF-
β1 (forward primer: 5′-TCGTCTGCATTGCACTTATGC-3′,
reverse primer: 5′-GTGGTGCCCTCTGAAATGAAA-3′), and
GAPDH (forward primer: 5′-CTCCACTCACGGCAAATTCA-
3′, reverse primer: 5′-GCCTCACCCCATTTGATGTT-3′).
Real-time PCR was performed using Power SYBR Green PCR
master mix (Applied Biosystem, Waltham, MA, United States)
and analysis of the data was performed by One-step RT PCR
(Applied Biosystem). Target gene expression was normalized to
GAPDH expression.
Measurement of Cytokine Production
Broncho-alveolar lavage (BAL) samples were collected via
tracheotomy using 600 µl of PBS and the cells were separated
from the BAL fluid by centrifugation at 1400 rpm for 5 min at
4◦C. For in vitro experiments, supernatants from BMMs or MH-S
after virus infection were carefully collected. Production of IFN-
β (BioLegend, San Diego, CA, United States), IL-12p40, GM-CSF,
and TNF-α (R&D System, Minneapolis, MN, United States) was
examined using ELISA kit.
Phenotypic Characterization of the Cells
To examine the absolute number of AM and other innate
immune cells, BAL cells were collected as above and perfused
lungs were isolated and minced through 70 µm cell strainer
using MEM. The cells were stained with FITC-conjugated
anti-CD11c (HL3), PE-conjugated anti-Siglec-F (E50-2440),
PerCP-conjugated anti-Ly6C (AL-21), PE-Cy7-conjugated anti-
Ly6G (1A8), APC-conjugated anti-CD11b (M1-70) or APC-
conjugated anti-F4/80 (BM8), and APC-Cy7-conjugated anti-
CD45 (30-F11) (all from BD Biosciences except anti-F4/80
from BioLegend). The cells were acquired using FACS LSR
II and flow cytometric data were analyzed by using FlowJo
software (Tree Star, San Carlos, CA, United States). We
defined CD45+Ly6C−Ly6G−CD11c+Sigleg-F+F4/80+ as AMs,
CD45+CD11b+Ly6C+Ly6G− for inflammatory monocytes, and
CD45+CD11b+Ly6G+Ly6C− for neutrophils.
Selective Depletion of Alveolar
Macrophages
To selectively deplete AM, 350 mg per mouse of clodronate-
encapsulated liposome (FormuMax Scientific Inc., CA,
United States) was given i.t. in a volume of 50 µl at 1 and
3 days before the RSV challenge with or without spore treatment.
To verify the depletion of AM, naïve mice were given control
liposome via i.t.
Virus Titration in the Lung
To determine the viral titers, lungs from RSV-infected mice were
isolated at day 4 post-infection. The lungs were minced through
70-µm cell strainer using cold MEM. Cell lysates were collected
and RSV titers were determined by plaque assay using HEp-2
cells. The virus titers in the whole lung were normalized to weight
of the lung tissue and indicated as PFU/g.
Lung Histology and Pathology Scoring
For histology studies, mice were administered with spore
and/or clodronate encapsulated liposome prior to RSV infection.
For control, mice were administered with PBS or control
liposome. At 4 days post infection, BAL fluid was removed
from lung and blood was perfused. Then, lungs were fixed
with 4% paraformaldehyde and embedded in paraffin. Lung
sections were produced and stained with Hematoxylin and Eosin
to examine the abnormalities. Four inflammatory parameters
were scored independently from 0 to 5 for each section:
alveolitis (inflammatory cells within alveolar spaces), interstitial
pneumonitis (increased thickness of alveolar walls associated
with inflammatory cells), peribronchiolitis (inflammatory cells
surrounding a bronchiole), and perivasculitis (inflammatory
cells surrounding a blood vessel). Slides were randomized, read
blindly, and scored for each parameter.
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In vivo or in vitro Spore Administration
and RSV Infection
In vivo mouse model, each mouse was administered with
either 1 × 109 CFU of spore or, PBS as a control, i.n. in a
volume of 20 µl at 5 days before the infection. Then, the mice
were infected i.t. with 2 × 106 PFU of live RSV A2. BMMs
or MH-S cell line were cultured in 12-well plate (1 × 106
cells/ml) with various ratio of spore for 24 h. Cells were washed
with PBS and then infected with 1 MOI of live RSV A2 for
additional 12 h.
Statistical Analysis
Results are presented as means ± SEM. Statistical differences
between two means were evaluated using unpaired Student t test.
For comparisons of multiple groups, one-way ANOVA was used.
Statistical significance was set at a P value of < 0.05.
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